# reload+after+2024-01-20 22:44:11.902871
address1§1600 West End Avenue
address2§Suite 1300
city§Nashville
state§TN
zip§37203
country§United States
phone§615 255 0068
website§https://www.cumberlandpharma.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
fullTimeEmployees§85
companyOfficers§[{'maxAge': 1, 'name': 'Mr. A. J. Kazimi MBA', 'age': 65, 'title': 'Founder, Chairman, President & CEO', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 897497, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John Michael Hamm', 'age': 67, 'title': 'Chief Financial Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 231378, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James Lowrance Herman', 'age': 68, 'title': 'Executive VP of National Accounts & Chief Compliance Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 352648, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jean W. Marstiller', 'age': 73, 'title': 'Senior VP of Administrative Services & Corporate Secretary', 'yearBorn': 1950, 'fiscalYear': 2022, 'totalPay': 282168, 'exercisedValue': 38535, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chris T. Bitterman', 'age': 58, 'title': 'Vice President of Sales & Marketing', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Adam S. Mostafa', 'age': 43, 'title': 'Managing Director', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Todd M. Anthony', 'age': 62, 'title': 'Vice President of Organizational Development', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erin Smith Gull', 'title': 'Senior Corporate Relations Associate', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.139
priceToSalesTrailing12Months§0.8490362
currency§USD
dateShortInterest§1702598400
forwardEps§0.14
exchange§NMS
quoteType§EQUITY
shortName§Cumberland Pharmaceuticals Inc.
longName§Cumberland Pharmaceuticals Inc.
firstTradeDateEpochUtc§1249997400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§fbb0fe28-9752-3ce1-bfca-efe25634b947
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
quickRatio§1.139
grossMargins§0.81723
ebitdaMargins§-0.0366
trailingPegRatio§None
